This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
by Sundeep Ganoria
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
Trading Rotation Kicks Off 2nd Half of 2025
by Mark Vickery
Tech stocks lagged after a very strong first half of the year, while healthcare led the way.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
by Kinjel Shah
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $78.83, moving 1.05% from the previous trading session.
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
by Kanishka Das
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
Merck Moves Past 50-Day Average: How to Play MRK Stock Now
by Kinjel Shah
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
by Zacks Equity Research
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
by Kinjel Shah
PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
by Kinjel Shah
SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
by Zacks Equity Research
EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
by Sundeep Ganoria
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
by Kinjel Shah
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.
Why the Market Dipped But Merck (MRK) Gained Today
by Zacks Equity Research
Merck (MRK) closed at $79.29 in the latest trading session, marking a +1.29% move from the prior day.
Merck (MRK) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $78.28, signifying a -3.31% move from its prior day's close.
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
by Zacks Equity Research
Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
by Ekta Bagri
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
by Kinjel Shah
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.
Here's Why Merck (MRK) Fell More Than Broader Market
by Zacks Equity Research
In the most recent trading session, Merck (MRK) closed at $80.32, indicating a -1.27% shift from the previous trading day.
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
by Kinjel Shah
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
Merck (MRK) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Merck (MRK) closed at $81.35 in the latest trading session, marking a +2.55% move from the prior day.
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
by Zacks Equity Research
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.